Study of barzolvolimab for cold hives or skin writing
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called barzolvolimab for people with cold-induced hives or a condition where scratching causes raised lines (symptomatic dermographism) that aren't well controlled by antihistamines. The study compares the drug to a placebo to see if it reduces itching and hives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have had cold hives or skin writing for at least 3 months.
- Your hives or skin writing must still bother you even though you take a daily non-drowsy antihistamine.
- You must be willing to keep taking the same antihistamine dose for 4 weeks before starting the study drug.
- You must not be pregnant or nursing, and if you could become pregnant or get someone pregnant, you must use highly effective birth control during and for 150 days after treatment.
- You must be able to complete a daily symptom diary and attend study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GTX-B001, in healthy people and those with a type of hives called chronic inducible urticaria (specifically cold-induced or scratch-induced hives). The goal is to see if it's safe and helps control symptoms that don't respond well to standard antihistamines.
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This study tests an investigational pill called THB335 for adults whose hives (itchy welts) keep appearing despite taking antihistamines. The goal is to see if this treatment can reduce itching and hives and improve quality of life.
Hear when a new Chronic Inducible Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.